Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 436

1.

Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs.

Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Miguel Rosales J, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Manuel Pascasio J, Esteban R, Mariño Z, Buti M.

J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30345-9. doi: 10.1016/j.jhep.2019.06.002. [Epub ahead of print]

PMID:
31203153
2.

Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity.

Martínez-Valle F, Riveiro-Barciela M, Salcedo MT, Merino-Casabiel X, Fernández-Codina A, Torres I, Esteban R, Buti M.

Ann Hepatol. 2019 Jan - Feb;18(1):215-219. doi: 10.5604/01.3001.0012.7916.

3.

Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6.

Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K, Lahser F, Jackson B, Shaughnessy M, Klopfer S, Yeh WW, Robertson MN, Hanna GJ, Barr E, Platt HL; C-BREEZE-2 Study Investigators.

J Viral Hepat. 2019 May 20. doi: 10.1111/jvh.13132. [Epub ahead of print]

PMID:
31108015
4.

Characterization of hepatitis B virus X gene quasispecies complexity in mono-infection and hepatitis delta virus superinfection.

Godoy C, Tabernero D, Sopena S, Gregori J, Cortese MF, González C, Casillas R, Yll M, Rando A, López-Martínez R, Quer J, González-Aseguinolaza G, Esteban R, Riveiro-Barciela M, Buti M, Rodríguez-Frías F.

World J Gastroenterol. 2019 Apr 7;25(13):1566-1579. doi: 10.3748/wjg.v25.i13.1566.

5.

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.

Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; Hepatitis Delta International Network (HDIN).

J Hepatol. 2019 May;70(5):1008-1015. doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27. Review.

PMID:
30982526
6.

Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study.

Sonneveld MJ, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Liaw YF, Hansen BE, Choi H, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Knegt RJ, Janssen HLA.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):538-544. doi: 10.1016/S2468-1253(19)30087-1. Epub 2019 Apr 9.

PMID:
30975477
7.

HEVnet: a One Health, collaborative, interdisciplinary network and sequence data repository for enhanced hepatitis E virus molecular typing, characterisation and epidemiological investigations.

Mulder AC, Kroneman A, Franz E, Vennema H, Tulen AD, Takkinen J, Hofhuis A, Adlhoch C; Members Of HEVnet.

Euro Surveill. 2019 Mar;24(10). doi: 10.2807/1560-7917.ES.2019.24.10.1800407.

8.

Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.

Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos K, Crans G, Flaherty J, Gaggar A, Marcellin P.

Lancet Gastroenterol Hepatol. 2019 Apr;4(4):296-304. doi: 10.1016/S2468-1253(19)30015-9. Epub 2019 Feb 20.

PMID:
30795958
9.

Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level.

Karimzadeh H, Kiraithe MM, Oberhardt V, Salimi Alizei E, Bockmann J, Schulze Zur Wiesch J, Budeus B, Hoffmann D, Wedemeyer H, Cornberg M, Krawczyk A, Rashidi-Alavijeh J, Rodríguez-Frías F, Casillas R, Buti M, Smedile A, Alavian SM, Heinold A, Emmerich F, Panning M, Gostick E, Price DA, Timm J, Hofmann M, Raziorrouh B, Thimme R, Protzer U, Roggendorf M, Neumann-Haefelin C.

Gastroenterology. 2019 May;156(6):1820-1833. doi: 10.1053/j.gastro.2019.02.003. Epub 2019 Feb 12.

10.

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1.

Zeuzem S, Bourgeois S, Greenbloom S, Buti M, Aghemo A, Lampertico P, Janczewska E, Lim SG, Moreno C, Buggisch P, Tam E, Corbett C, Willems W, Vijgen L, Fevery B, Ouwerkerk-Mahadevan S, Ackaert O, Beumont M, Kalmeijer R, Sinha R, Biermer M; OMEGA-1 study team.

Hepatology. 2019 Jun;69(6):2349-2363. doi: 10.1002/hep.30527. Epub 2019 Mar 14.

PMID:
30693573
11.

Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity.

Martínez-Valle F, Riveiro-Barciela M, Salcedo MT, Merino-Casabiel X, Fernández-Codina A, de Torres I, Esteban R, Buti M.

Ann Hepatol. 2018 Dec 13;18(1):215-219. doi: 10.5604/01.3001.0012.7916.

12.

Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients.

Suárez E, Buti M, Rodríguez M, Prieto M, Pascasio-Acevedo JM, Casanovas T, Crespo J, Tapiador JAR, Gómez-Rodríguez R, Figueruela B, Diago M, Morillas RM, Zozaya JM, Calleja JL, Casado M, Molina E, Fuentes J, Simón MA.

Eur J Gastroenterol Hepatol. 2019 Feb;31(2):267-271. doi: 10.1097/MEG.0000000000001289.

PMID:
30576297
13.

Decompensated Liver Disease due to Primary Hepatic Amyloidosis: Is Liver Transplantation Still Mandatory?

Riveiro-Barciela M, Gironella M, Senín A, Salcedo MT, Merino-Casabiel X, Castells L, Esteban R, Buti M, Martínez-Valle F.

Hepatology. 2019 Jun;69(6):2701-2703. doi: 10.1002/hep.30464. Epub 2019 Mar 7. No abstract available.

PMID:
30561765
14.

Determination of Free Soluble Phenolic Compounds in Grains of Ancient Wheat Varieties ( Triticum sp. pl.) by Liquid Chromatography-Tandem Mass Spectrometry.

Montevecchi G, Setti L, Olmi L, Buti M, Laviano L, Antonelli A, Sgarbi E.

J Agric Food Chem. 2019 Jan 9;67(1):201-212. doi: 10.1021/acs.jafc.8b05629. Epub 2018 Dec 20.

PMID:
30525569
15.

Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant.

Perales C, Chen Q, Soria ME, Gregori J, Garcia-Cehic D, Nieto-Aponte L, Castells L, Imaz A, Llorens-Revull M, Domingo E, Buti M, Esteban JI, Rodriguez-Frias F, Quer J.

Infect Drug Resist. 2018 Nov 8;11:2207-2210. doi: 10.2147/IDR.S172226. eCollection 2018.

16.

Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?

Riveiro-Barciela M, Muñoz-Couselo E, Fernandez-Sojo J, Diaz-Mejia N, Parra-López R, Buti M.

J Hepatol. 2019 Mar;70(3):564-566. doi: 10.1016/j.jhep.2018.10.020. Epub 2018 Nov 28. No abstract available.

PMID:
30503040
17.

Healthcare value of implementing hepatitis C screening in the adult general population in Spain.

Buti M, Domínguez-Hernández R, Casado MÁ, Sabater E, Esteban R.

PLoS One. 2018 Nov 28;13(11):e0208036. doi: 10.1371/journal.pone.0208036. eCollection 2018.

18.

HDV evolution-will viral resistance be an issue in HDV infection?

Tabernero D, Cortese MF, Buti M, Rodriguez-Frias F.

Curr Opin Virol. 2018 Oct;32:100-107. doi: 10.1016/j.coviro.2018.10.003. Epub 2018 Nov 8. Review.

PMID:
30415162
19.

Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis.

Yeo YH, Ho HJ, Yang HI, Tseng TC, Hosaka T, Trinh HN, Kwak MS, Park YM, Fung JYY, Buti M, Rodríguez M, Treeprasertsuk S, Preda CM, Ungtrakul T, Charatcharoenwitthaya P, Li X, Li J, Zhang J, Le MH, Wei B, Zou B, Le A, Jeong D, Chien N, Kam L, Lee CC, Riveiro-Barciela M, Istratescu D, Sriprayoon T, Chong Y, Tanwandee T, Kobayashi M, Suzuki F, Yuen MF, Lee HS, Kao JH, Lok AS, Wu CY, Nguyen MH.

Gastroenterology. 2019 Feb;156(3):635-646.e9. doi: 10.1053/j.gastro.2018.10.027. Epub 2018 Oct 17.

PMID:
30342034
20.

Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.

Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, Chuang WL, Tabak F, Mehta R, Petersen J, Guyer W, Jump B, Chan A, Subramanian M, Crans G, Fung S, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HLY.

Dig Dis Sci. 2019 Jan;64(1):285-286. doi: 10.1007/s10620-018-5294-y.

PMID:
30324553

Supplemental Content

Loading ...
Support Center